India, Nov. 8 -- EDAP TMS S.A. or FocalTherics (FOCL), a robotic focal therapy company, recently announced financial results for the third quarter, noting a lower loss arising from increased sales.
The company develops, manufactures, and markets minimally invasive medical devices that use focused ultrasound therapies to treat various conditions. The Focal One Robotic HIFU is a flagship platform that combines advanced imaging, real-time planning, robotic precision and HIFU technology for procedures such as the focal ablation of prostate cancer tissue.
Q3 Financial Highlights:
Net loss for the third quarter came to $4.46 million or $0.10 per share, slightly lower than the loss of $5.94 million or $0.16 per share was recorded in the same pe...